Graves Orbitopathy With Decreasing Vision
A 52-year-old woman with Graves disease treated with methimazole and euthyroid for 3 months reports 8 months of progressive diplopia and decreasing vision in the right eye. She smokes 30 pack-years. Acuity is 20/40 right and 20/25 left, with reduced color saturation and a relative afferent pupillary defect on the right. Intraocular pressure is 24 mmHg right and 18 mmHg left; exophthalmometry is 27 mm right and 24 mm left. There is mild right disc swelling and an inferior arcuate field defect. She reports constant diplopia on upgaze and right gaze. CT shows enlarged extraocular muscles with apical crowding and no orbital mass. She has no known diabetes and takes no other medication. She wants cosmetic eyelid surgery later and asks whether radioiodine is safe and whether steroids are really necessary.
1. How would you confirm dysthyroid optic neuropathy, and how urgently would you treat? Compare intravenous glucocorticoids with orbital decompression.
Read the worked answer
Diagnosis. Dysthyroid optic neuropathy is a clinical diagnosis supported by apical crowding on CT. Features here are reduced acuity, reduced color saturation, a relative afferent pupillary defect, disc swelling, and a field defect. The differential includes compressive optic neuropathy from a mass, diabetic papillopathy, and ischemic optic neuropathy, but the CT and thyroid history make TED most likely. This is sight-threatening and needs treatment within days, not weeks.
Steroids versus decompression. First-line is intravenous methylprednisolone, typically 500–1000 mg weekly for 6 weeks, or 1 g/day for 3 days followed by oral taper. About two-thirds respond, usually within 1–2 weeks. Risks include hyperglycemia, hypertension, infection, mood change, and avascular necrosis. If vision fails to improve, or if the patient cannot tolerate steroids, or optic neuropathy is severe at presentation, urgent orbital decompression is indicated. Decompression is definitive but carries risks of diplopia, infraorbital numbness, and cerebrospinal fluid leak. Do not use low-dose oral steroids alone for optic neuropathy.
Monitoring. Check acuity, color, pupils, fields, and IOP daily initially. Coordinate with endocrinology and anesthesia. Start smoking cessation immediately.
2. What would you advise about radioiodine, smoking, and the timing of rehabilitative surgery?
Read the worked answer
Radioiodine. Avoid radioiodine in active moderate-to-severe Graves orbitopathy, particularly in a smoker, because it can worsen inflammation and optic neuropathy. If thyroid control requires it, give prophylactic glucocorticoid cover and only after the orbitopathy is stable or treated. Methimazole can continue; monitor liver function and ANCA if used long term.
Smoking. This is the most important modifiable risk factor. It doubles the risk of progression and reduces response to treatment. Offer a structured cessation program, nicotine replacement, and follow-up. Explain that continued smoking may make surgery more difficult and recurrence more likely.
Timing of rehabilitation. Wait until the orbitopathy has been inactive for at least 6 months and vision is stable. The usual sequence is orbital decompression first if there is optic neuropathy or marked proptosis, then strabismus surgery for diplopia, then eyelid surgery for retraction. Do not perform cosmetic eyelid surgery during active disease. If she needs urgent decompression now, that takes priority. Arrange joint thyroid-eye clinic follow-up.